Market news
Every market development we have covered, newest first.
10 dated market items. Most recent: Microdose semaglutide protocols spread, and they are not comparable (2026-06-05).
All-in monthly cost at 2.4 mg
Stories in this category
Microdose semaglutide protocols spread, and they are not comparable
Fractional weekly doses below the labelled starting dose are sold at lower prices. They do not m…
New entrants push compounded semaglutide toward $86 a month
A nationwide platform launched at $86 for compounded semaglutide, well below the established ban…
Compounded semaglutide availability tightens again
Enforcement changes through spring 2026 left availability uneven and programme-dependent.…
Generic semaglutide launches in India and Canada
Patents lapsed across roughly ten markets in 2026. US patents run into the early 2030s.…
Hims closes its compounded semaglutide programme to new patients
Following a settlement with Novo Nordisk, one of the largest platforms exits compounded semaglut…
Telehealth platforms restructure around brand-only models
Membership billed separately from medication became the dominant structure at the large consumer…
Novo Nordisk sues a major telehealth platform over compounded semaglutide
Litigation between the manufacturer and the largest consumer platforms reshaped the market faste…
Pharmacies pivot to B12 combinations after the April deadline
Semaglutide combined with another active ingredient is argued not to be essentially a copy. The …
Wegovy supply normalises after two years of constraint
Manufacturing capacity caught up with demand, which set up the February shortage resolution.…
Compounded versions reached roughly 30% of US GLP-1 supply
The scale of the compounded market at its 2024 peak explains how much had to restructure in 2025…
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.